We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

Me’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an ...

After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.

-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, privacy concerns over 23andMe's genetic data, importance of biotechnology ...

A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led by the company's former CEO Anne Wojcicki, the company announced. The ...

Regeneron had previously been the winning bidder in a bankruptcy auction for virtually all of 23andMe’s assets, but it's now lost out after bidding was reopened. Back to Top Albany Business Review ...

23andMe co-founder and CEO Anne Wokcicki won back control of the genetic-test company after a prolonged bankruptcy fight that at one point was won by Regeneron.

That means Wojcicki’s nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe’s assets for $305 million. The transaction — which arrives more than three ...

The case came after New York-based biotech giant Regeneron Pharmaceuticals announced May 19 its plan to purchase 23andMe in a $256 million deal. That deal has since faced new challenges in ...